6501-72-0
6501-72-0 structure
- Name: VGX-1027(Git-27)
- Chemical Name: 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
- CAS Number: 6501-72-0
- Molecular Formula: C11H11NO3
- Molecular Weight: 205.210
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2016-02-05 02:49:00
- Modify Date: 2024-01-03 16:45:00
-
VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.IC50 value: Target: immunomodulatorAdministration of VGX-1027 to NOD mice with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors markedly reduced the cumulative incidence of diabetes and insulitis. In addition, VGX-1027 given either i.p. or p.o. to CBA/H mice made diabetic with multiple low doses of streptozotocin successfully counteracted the development of destructive insulitis and hyperglycemia [1]. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-gamma and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA [2]. VGX-1027 inhibited both proliferation of enterobacterial antigen-reactive CD4+CD25- T cells in vitro and the development of clinical and histological signs of colitis in vivo [3].
| Name | 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid |
|---|---|
| Synonyms |
GIT 27
3-phenyl-4,5-dihydro-5-isoxazoleacetic acid 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID (3-Phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid 5-Isoxazoleacetic acid, 4,5-dihydro-3-phenyl- VGX-1027 |
| Description | VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.IC50 value: Target: immunomodulatorAdministration of VGX-1027 to NOD mice with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors markedly reduced the cumulative incidence of diabetes and insulitis. In addition, VGX-1027 given either i.p. or p.o. to CBA/H mice made diabetic with multiple low doses of streptozotocin successfully counteracted the development of destructive insulitis and hyperglycemia [1]. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-gamma and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA [2]. VGX-1027 inhibited both proliferation of enterobacterial antigen-reactive CD4+CD25- T cells in vitro and the development of clinical and histological signs of colitis in vivo [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 381.4±34.0 °C at 760 mmHg |
| Melting Point | 159 °C |
| Molecular Formula | C11H11NO3 |
| Molecular Weight | 205.210 |
| Flash Point | 184.5±25.7 °C |
| Exact Mass | 205.073898 |
| PSA | 58.89000 |
| LogP | 1.16 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
| Index of Refraction | 1.601 |
|
~%
6501-72-0 |
| Literature: GANIAL IMMUNOTHERAPEUTICS INC. Patent: WO2006/97273 A1, 2006 ; Location in patent: Page/Page column 13 ; |
|
~%
6501-72-0 |
| Literature: Eichinger, Karl; Wokurek, Michael; Zauner, Bernd; Rostami, Mohammad Reza Synthetic Communications, 1997 , vol. 27, # 16 p. 2733 - 2742 |
|
~%
6501-72-0 |
| Literature: Stosic-Grujicic, Stanislava; Cvetkovic, Ivana; Mangano, Katia; Fresta, Massimo; Maksimovic-Ivanic, Danijela; Harhaji, Ljubica; Popadic, Dusan; Momcilovic, Miljana; Miljkovic, Djordje; Kim, Joseph; Al Abed, Yousef; Nicoletti, Ferdinando Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 3 p. 1038 - 1049 |
